Liminatus Pharma shareholders approve reverse stock split authorization up to 1-for-50 at annual meeting

Liminatus Pharma, Inc.

Elected Class I directors Nicholas Fernandez and Dr. Ji Yeon Baek with ~23.4M votes for each; broker non-votes 8.8M.
Ratified WithumSmith+Brown as independent auditor for FY2026; 31.5M for, 0.89M against, 63k abstain.
Approved reverse stock split authorization up to 1-for-50 at Board's discretion to meet Nasdaq minimum bid price; 30.1M for, 2.3M against.
Quorum of 48.31% (32.4M shares) represented at the August 3, 2026 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.